UniProtKB/Swiss-Prot P15289 : Variant p.Pro425Thr
Arylsulfatase A
Gene: ARSA
Feedback ?
Variant information
Variant position:
425
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:
LP/P [Disclaimer : Variants classification is intended for research purposes only, not for clinical and diagnostic use . The label disease variant is assigned according to literature reports on probable disease-association that can be based on theoretical reasons. This label must not be considered as a definitive proof for the pathogenic role of a variant. ]
The variants are classified into three categories: LP/P, LB/B and US.LP/P: likely pathogenic or pathogenic. LB/B: likely benign or benign. US: uncertain significance
Residue change:
From Proline (P) to Threonine (T) at position 425 (P425T, p.Pro425Thr).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:
Change from medium size and hydrophobic (P) to medium size and polar (T)
The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:
-1
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another: Lowest score: -4 (low probability of substitution).Highest score: 11 (high probability of substitution). More information can be found on the following page
Variant description:
In MLD; juvenile-onset; retains about 12% of specific enzyme activity; the mutant protein is unstable; results in more rapid enzyme degradation in lysosomes; addition of the cysteine protease inhibitor leupeptin increases the amount of the enzyme activity; displays a modest reduction in the octamerization process of the enzyme at low pH.
Any additional useful information about the variant.
Other resources:
Links to websites of interest for the variant.
Sequence information
Variant position:
425
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:
507
The length of the canonical sequence.
Location on the sequence:
HSDTTADPACHASSSLTAHE
P PLLYDLSKDPGENYNLLGGV
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Sequence annotation in neighborhood:
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Literature citations
Metachromatic leucodystrophy in Portugal-finding of four new molecular lesions: C300F, P425T, g.1190-1191insC, and g.2408delC.
Marcao A.; Amaral O.; Pinto E.; Pinto R.; Sa Miranda M.C.;
Hum. Mutat. 13:337-338(1999)
Cited for: VARIANTS MLD PHE-300 AND THR-425;
Biochemical characterization of two (C300F, P425T) arylsulfatase A missense mutations.
Marcao A.; Simonis H.; Schestag F.; Sa Miranda M.C.; Gieselmann V.;
Am. J. Med. Genet. A 116:238-242(2003)
Cited for: CHARACTERIZATION OF VARIANTS MLD PHE-300 AND THR-425;
Oligomerization capacity of two arylsulfatase A mutants: C300F and P425T.
Marcao A.; Azevedo J.E.; Gieselmann V.; Sa Miranda M.C.;
Biochem. Biophys. Res. Commun. 306:293-297(2003)
Cited for: CHARACTERIZATION OF VARIANTS MLD PHE-300 AND THR-425;
Disclaimer:
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.